Company Overview of Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of product candidates for patients with cystic fibrosis (CF). CF is a life-shortening genetic disease. Its lead product candidate is N91115, a small molecule that is in Phase Ib clinical trial, which addresses a defect in cystic fibrosis transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. The company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquartered in Boulder, Colorado.
3122 Sterling Circle
Boulder, CO 80301
Founded in 2007
Key Executives for Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Key Developments
Similar Private Companies By Industry
|rEVO Biologics, Inc.||United States|
|CytoVale Inc.||United States|
|Aubrey Inc.||United States|
|Sanofi Pasteur VaxDesign Corporation||United States|
|Osprey Biomedical Corp.||United States|
Recent Private Companies Transactions
November 18, 2014
To contact Nivalis Therapeutics, Inc., please visit www.nivalis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.